Fundamental Truths Concerning Seattle Genetics’ Co-Founder, Clay Siegall

Clay B. Siegall is a Ph.D. holder and a time-proven scientist. His involvement revolves around research, where he focuses on cancer therapies. Clay earned his B.S in Zoology from the University of Maryland and again pursued his Ph.D. from George Washington University. He is committed to finding a lasting solution for the cancer patients and their loved ones. His career life begun taking shape when he worked with National Cancer Institute, National Institutes of Health, between 1988 and 1991. Again in 1991, he started working with the Bristol-Myers Squibb Pharmaceutical Research Institute until 1997. Dr. Siegall appreciates the invaluable skills he gained in those institutions that he served before co-founding Seattle Genetics.

 

General Information About Seattle Genetics

 

Siegall co-founded Seattle in 1998, and he serves there as the president, CEO and board chairman. The primary reason for the inception was to enhance cancer therapies. There was a great motivation that came from Clay’s father’s illness. Siegall’s father was diagnosed with cancer when he was 19. He suffered from the life-threatening disease for five years, and Clay was watching. Mr. Clay Siegall got motivated to pursue cancer treatment so as to deliver the patients from the agony. The company has registered great milestones so far. They have succeeded in creating drugs that are FDA approved, the major one being in 2011, where their first ADC products were approved.

 

Various Administrative Positions Held by Clay Siegall

 

Mr. Clay served at Onyx Pharmaceuticals, Inc. as the Vice President and Chief Financial Officer. As well, he served as an independent director for Ultragenyx. The pharmaceuticals firm took him in because they believed in his proven proficiency in the biopharmaceutical industry. When joining the company, Clay appreciated the significant progress they had made in their clinical programs. Being a supporter of development, he pledged his allegiance in working with Ultragenyx in achieving greater goals ahead of them.

 

Clay’s Appointment at Mirna Therapeutics Inc.

 

In January 2013, Clay experienced a boost in his career when he got appointed to the board of directors at Mirna Therapeutics Inc. The firm mainly focuses on creation and commercialization of microRNA (miRNA) therapeutics. Being an exciting environment for cancer research, it got him serving in his most relevant area of specialty.